A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Sponsor
AstraZeneca
Study ID
NCT06610526
Phase
PHASE4
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.

Key Dates

Start date
Aug 23, 2024
Status verified
Jan 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
731 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
    Dapagliflozin 10 mg once daily

Primary Outcome Measure

Time to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death. [ Time Frame: Up to a median follow-up time of 24 months ]

Related Studies